South Africa’s Aspen Pharmacare is continuing along the path of offloading assets that no longer fit into its strategy, using the proceeds to pay off its substantial debt pile and reinvest in areas of greater strategic focus. Half-a-dozen products currently offered in its local market are now on their way to Switzerland’s Acino.

Celltrion has bought a portfolio of selected products in the Asia-Pacific region from Takeda, marking a foray into small-molecule drugs.

In continuing strategy to shed non-core assets globally, Japanese firm will sell portfolio of selected products in Asia-Pacific to Korean biosimilars giant Celltrion.

Danish firm picks up portfolio and manufacturing sites, along with around 600 employees.